Justesenmcpherson7416

89.

To investigate the usefulness of cell-free DNA (cfDNA) in patients with oligometastasis.

This study included oligometastatic colorectal cancer (CRC) patients who underwent ablative irradiation using stereotactic body radiotherapy or proton beam therapy for metastatic lesions at a single institution. cfDNA was purified from the plasma of pretreated patients and gene mutations were analyzed by next-generation sequencing. Progression-free survival (PFS) was statistically compared according to gene mutation, clonality or allele frequency.

A total of 20 patients were analyzed. Mutations were detected in the following genes; TP53 (45%), APC (40%), KRAS (15%), PIK3CA (15%), NF1 (5%), BRCA1 (5%), ERBB2 (5%), FBXW7 (5%), KIT (10%), and HRAS (10%). Patients with multi-clonality of gene mutation showed tendency for poor PFS (p=0.07). Among 7 patients whose metastatic site was the lung, those with no cfDNA detected had significantly better PFS than those with cfDNA (p=0.02).

cfDNA profiles could be predictive tools for early recurrence of oligometastatic CRC patients after ablative radiotherapy.

cfDNA profiles could be predictive tools for early recurrence of oligometastatic CRC patients after ablative radiotherapy.

Preclinical studies on metformin use and endometrial cancer have been promising but epidemiological studies have reported variable results. This study aimed to assess if metformin use is associated with endometrial cancer aggressiveness and survival in women with type 2 diabetes (T2D).

This retrospective hospital-based cohort consisted of women with T2D who were treated for endometrial cancer at the Oulu University Hospital, Finland, between 2007 and 2014.

The sample size was 121 patients 58 metformin users and 63 metformin non-users. Intriguingly, type 2 histology, deep myometrial invasion and the presence of lymphovascular invasion were more common in the metformin user group. However, metformin use showed no association with overall survival and progression-free survival.

Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D.

Metformin use was associated with poorer prognostic factors in endometrial cancer patients with T2D.

The GastroPanel

test (Biohit Oyj) is interpreted by the GastroSoft

application distinguishing eight biomarker profiles, of which five profiles have a morphological equivalent in the Updated Sydney System (USS) classification of gastritis, and 3 others specify functional disorders of the stomach 1) high acid output, 2) low acid output, and 3) effects of proton pump inhibitor (PPI) medication. This study evaluated the prevalence of these biomarker profiles in dyspeptic patients.

A cross-sectional study was designed to assess the point prevalence of these biomarker profiles in a random sample of 500 subjects derived from our archives of GastroPanel

samples.

Reflux symptoms were reported by 35.2% and use of PPI medication by 36.8% of the study subjects. Biomarker profile 2 (high acid output) was the second most common GastroPanel

profile in this cohort; 31.2%, second only (33.6%) to profile 1 (healthy stomach). Hp-infection was detected in 25.0% of the subjects. Profiles related to use of PPI (low acid output, PPI effect) were found in 7.4% of the cases. AG was uncommon, diagnosed in 14 patients only (2.8%).

These data are derived from the population with the highest frequency of dyspepsia, and the results might have widespread implications in diagnostic and screening practices.

These data are derived from the population with the highest frequency of dyspepsia, and the results might have widespread implications in diagnostic and screening practices.

We investigated the prognostic influence of both hepatoma-derived growth factor (HDGF) and p53 expression in head and neck cancer.

HDGF and p53 immunostaining was scored based on staining intensities and percentage of tumor cells stained using tissue microarray composed of total 102 head and neck cancer samples.

Over-expression of HDGF and p53 was observed in cancer compared with adjacent normal tissues (p<0.001). In multivariate analyses, tumors with higher nuclear and cytoplasmic HDGF staining scores (p=0.019), and tumors with cN1-cN2 (compared with cN0) (p=0.014), were associated with worse overall survival.

The increased expression of HDGF and p53 in the tumor compared with adjacent normal tissues could be a risk factor for tumorigenesis. Increased nuclear and cytoplasmic expression of HDGF, and cN staging correlated with overall survival and negatively influenced prognosis in head and neck cancer.

The increased expression of HDGF and p53 in the tumor compared with adjacent normal tissues could be a risk factor for tumorigenesis. Increased nuclear and cytoplasmic expression of HDGF, and cN staging correlated with overall survival and negatively influenced prognosis in head and neck cancer.

Chloride intracellular channel protein (CLIC1), E- and P-cadherin (Ecad, Pcad) are certified factors of aggressivity, but they have not been studied in breast cancer to date. https://www.selleckchem.com/products/pf-06650833.html The aim was to study CLIC1, Ecad and Pcad impact on breast cancer in terms of defining new high-risk subgroups.

Ninety-seven breast cancer biopsies were immunohistochemically evaluated for CLIC1, Ecad and Pcad expression related to molecular subtypes. CLIC1 expression was assessed in both tumor cells (CLIC1T) and blood vessels (CLIC1V).

For 23% of Luminal A cases, both cadherins and CLIC1V were positive. Luminal B/HER2 subtype, had two specific phenotypes Ecad-/Pcad-/CLIC1T-/CLIC1V+ and Ecad+/Pcad-/CLIC1T-/CLIC1V+. All TNBC cases were clustered into two subgroups 60% were Ecad+/Pcad+/CLIC1T+/CLIC1V+) while 40% were Ecad+/Pcad+/CLIC1T+/CLIC1V-).

CLIC1, Ecad and Pcad association stratifies molecular types of breast cancer in subgroups that may explain different response to therapy and different aggressiveness previously observed by other authors within the same molecular subtype.

CLIC1, Ecad and Pcad association stratifies molecular types of breast cancer in subgroups that may explain different response to therapy and different aggressiveness previously observed by other authors within the same molecular subtype.